Evidence map›Paper›PMID 32899969›Full record

ArticleVaccines2020

Characterization of the

Sílvia A Sousa, António M M Seixas, Manoj Mandal, Manuel J Rodríguez-Ortega, Jorge H Leitão

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Antibodies toMicroorganisms · 2026
    Article
  3. Article
  4. Article
  5. Vaccines · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Novel Chimeric Vaccine Candidate Development againstInternational journal of environmental research and public health · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Sílvia A SousaiBB-Institute for Bioengineering and Biosciences, 1049-001 Lisbon, Portugal.ORCID 0000-0001-9291-9169
António M M SeixasiBB-Institute for Bioengineering and Biosciences, 1049-001 Lisbon, Portugal.ORCID 0000-0002-3484-3474
Manoj MandaliBB-Institute for Bioengineering and Biosciences, 1049-001 Lisbon, Portugal.
Manuel J Rodríguez-OrtegaDepartament of Biochemistry and Molecular Biology, Córdoba University, 14071 Córdoba, Spain.ORCID 0000-0002-8744-7045
Jorge H LeitãoiBB-Institute for Bioengineering and Biosciences, 1049-001 Lisbon, Portugal.ORCID 0000-0001-8850-274X
Institute for Biotechnology and Bioengineering · PTUniversity of Córdoba · ES

Funding

Fundação para a Ciência e a Tecnologia - Portugal PTDC/BIA-MIC/1615/2014IBB - Institute dor Bioengineering and Biosciences UIDB/04565/2020
6 · The paper itself

Abstract

Infections by the

Indexed as

Burkholderia cepacia complexcystic fibrosisimmunoreactive proteinsimmunoreactivityliquid chromatography–tandem mass spectrometry (LC-MS/MS)serum samplessurface-exposed moieties

Identifiers

PMID32899969
PMCPMC7565204
OpenAlexW3083025751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.